GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » TriSalus Life Sciences Inc (NAS:TLSI) » Definitions » Price-to-Owner-Earnings

TLSI (TriSalus Life Sciences) Price-to-Owner-Earnings : (As of Dec. 13, 2024)


View and export this data going back to 2023. Start your Free Trial

What is TriSalus Life Sciences Price-to-Owner-Earnings?

As of today (2024-12-13), TriSalus Life Sciences's share price is $3.91. TriSalus Life Sciences does not have enough data to calculate Owner Earnings per Share (TTM), so as pPrice-to-Owner-Earnings.


The historical rank and industry rank for TriSalus Life Sciences's Price-to-Owner-Earnings or its related term are showing as below:


TLSI's Price-to-Owner-Earnings is not ranked *
in the Medical Devices & Instruments industry.
Industry Median: 32.42
* Ranked among companies with meaningful Price-to-Owner-Earnings only.

As of today (2024-12-13), TriSalus Life Sciences's share price is $3.91. TriSalus Life Sciences's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2024 was $-2.49. Therefore, TriSalus Life Sciences's PE Ratio (TTM) for today is At Loss.

As of today (2024-12-13), TriSalus Life Sciences's share price is $3.91. TriSalus Life Sciences's EPS without NRI for the trailing twelve months (TTM) ended in was $-2.19. Therefore, TriSalus Life Sciences's PE Ratio without NRI for today is At Loss.


TriSalus Life Sciences Price-to-Owner-Earnings Historical Data

The historical data trend for TriSalus Life Sciences's Price-to-Owner-Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

TriSalus Life Sciences Price-to-Owner-Earnings Chart

TriSalus Life Sciences Annual Data
Trend Dec21 Dec22 Dec23
Price-to-Owner-Earnings
- - -

TriSalus Life Sciences Quarterly Data
Dec21 Mar22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Price-to-Owner-Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of TriSalus Life Sciences's Price-to-Owner-Earnings

For the Medical Devices subindustry, TriSalus Life Sciences's Price-to-Owner-Earnings, along with its competitors' market caps and Price-to-Owner-Earnings data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


TriSalus Life Sciences's Price-to-Owner-Earnings Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, TriSalus Life Sciences's Price-to-Owner-Earnings distribution charts can be found below:

* The bar in red indicates where TriSalus Life Sciences's Price-to-Owner-Earnings falls into.



TriSalus Life Sciences Price-to-Owner-Earnings Calculation

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume. (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

TriSalus Life Sciences's Price-to-Owner-Earnings for today is calculated as

Price-to-Owner-Earnings=Share Price/Owner Earnings per Share (TTM)
=3.91/0.00
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


TriSalus Life Sciences  (NAS:TLSI) Price-to-Owner-Earnings Explanation

For how to get Owner Earnings per Share (TTM), please click.


TriSalus Life Sciences Price-to-Owner-Earnings Related Terms

Thank you for viewing the detailed overview of TriSalus Life Sciences's Price-to-Owner-Earnings provided by GuruFocus.com. Please click on the following links to see related term pages.


TriSalus Life Sciences Business Description

Traded in Other Exchanges
N/A
Address
6272 W. 91st Avenue, Westminster, CO, USA, 80031
TriSalus Life Sciences Inc is engaged in the research, development, and sales of innovative drug delivery technology and immune-oncology therapeutics to improve outcomes in difficult-to-treat liver and pancreatic cancer. It is developing and marketing two product lines?Pressure Enabled Drug Delivery (PEDD) infusion systems, in use today, and an investigational agent, nelitolimod (SD-101), which shows potential to enhance immune system response in the treatment of hepatocellular cancer, pancreatic cancer and other liver solid tumors. TriNav is the newest therapy delivery device with SmartValve technology for the proprietary PEDD approach.
Executives
Mats Wahlstrom director, 10 percent owner 500 GOLDEN RIDGE ROAD, SUITE 100, GOLDEN CO 80401
Mary T Szela director, officer: CEO and President 10835 ROAD TO THE CURE, SUITE 205, SAN DIEGO CA 92121
George Kelly Martin director C/O TRISALUS LIFE SCIENCES, INC., 6272 W. 91ST AVENUE, WESTMINSTER CO 80031
Jodi Devlin officer: President, Therapeutics C/O TRISALUS LIFE SCIENCES, INC., 6272 W. 91ST AVENUE, WESTMINSTER CO 80031
James Alecxih officer: President, Device Technology C/O NEVRO CORP., 1800 BRIDGE PARKWAY, REDWOOD CITY CA 94065
Bryan F. Cox officer: Chief Scientific & Manufact. C/O TRISALUS LIFE SCIENCES, INC., 6272 W. 91ST AVENUE, WESTMINSTER CO 80031
Kerry R Hicks director C/O HEALTHGRADES.COM, 44 UNION BLVD SUITE 600, LAKEOOD CO 80228
Jennifer Stevens officer: Chief Regulatory Officer C/O TRISALUS LIFE SCIENCES, INC., 6272 W. 91ST AVENUE, WESTMINSTER CO 80031
Richard Marshak officer: Sr.VP, Corp. Dev. & Strategy C/O TRISALUS LIFE SCIENCES, INC., 6272 W. 91ST AVENUE, WESTMINSTER CO 80031
Anil K. Singhal director C/O TRISALUS LIFE SCIENCES, INC., 6272 W. 91ST AVENUE, WESTMINSTER CO 80031
Sean Murphy director, officer: Chief Financial Officer C/O NOVAN, INC., 4222 EMPEROR BOULEVAND, SUITE 200, DURHAM NC 27703
Arjun Jj Desai director C/O TRISALUS LIFE SCIENCES, INC., 6272 W. 91ST AVENUE, WESTMINSTER CO 80031
Steven C Katz officer: Chief Medical Officer C/O TRISALUS LIFE SCIENCES, INC., 6272 W. 91ST AVENUE, WESTMINSTER CO 80031
Von Eschenbach Andrew C. director C/O BLCO, 400 SOMERSET CORPORATE BLVD., BRIDGEWATER NJ 08807
Equity Ab Frankenius 10 percent owner BOX 984, BORAS V7 SE-501 10